Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel Conditions
Rhea-AI Summary
Moolec Science (NASDAQ: MLEC) was granted continued listing by a Nasdaq Hearings Panel, subject to specific conditions and timelines. The Panel acknowledged bid-price compliance effective January 16, 2026, after a January 5, 2026 reverse stock split.
The Panel retained jurisdiction through May 13, 2026 and noted the company filed its Form 20-F for year-ended June 30, 2025 on December 29, 2025. Conditions include updates on derecognition by end-February 2026, pro forma financials by end-March 2026, public disclosure of compliance actions by May 13, 2026, and demonstration of full compliance by May 13, 2026.
Positive
- Bid-price compliance achieved on Jan 16, 2026
- Form 20-F filed on Dec 29, 2025
- Panel accepted a plan to regain equity compliance
Negative
- Continued listing remains conditional through May 13, 2026
- Must deliver pro forma financials by end of March 2026
- Required updates on derecognition proceedings by end-Feb 2026
Market Reaction
Following this news, MLEC has declined 6.15%, reflecting a notable negative market reaction. Argus tracked a peak move of +13.2% during the session. Our momentum scanner has triggered 13 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $6.26. This price movement has removed approximately $309K from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
MLEC was down 2.27% with no peers appearing in the momentum scanner and mixed moves across comparable biotech names, pointing to stock-specific trading rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Nasdaq equity exception | Positive | +10.6% | Nasdaq Staff memo supporting exception through June 29, 2026 on equity rule. |
| Jan 22 | Nasdaq panel decision | Positive | +4.6% | Panel grants exception to regain stockholders’ equity compliance by June 29, 2026. |
| Jan 05 | Share consolidation effective | Neutral | +3.9% | 15-for-1 share consolidation becomes effective and reflected in trading quotes. |
| Dec 31 | Non-compliance notice | Negative | -4.2% | Nasdaq letter citing failure to meet $2.5M stockholders’ equity and net income rules. |
| Dec 31 | Share consolidation plan | Neutral | -4.2% | Announcement of 15-for-1 consolidation plan intended to restore minimum bid price. |
Recent Nasdaq-compliance and balance-sheet announcements have generally seen price moves aligning with the underlying news tone.
Over the past months, Moolec has focused on Nasdaq compliance and capital structure changes. Shareholders approved and then implemented a 15-for-1 share consolidation effective January 5, 2026 to address bid-price issues. Derecognition gains from subsidiary bankruptcies in late 2025 materially lifted stockholders’ equity, supporting exceptions under Listing Rule 5550(b)(1). The latest Panel decision on continued listing extends this trajectory, formalizing conditions and timelines for full compliance.
Market Pulse Summary
The stock is down -6.2% following this news. A negative reaction despite the conditional continued listing could fit concerns about execution risks. The Panel’s decision hinges on multiple deadlines through May 13, 2026 for derecognition updates, pro forma financials, and equity compliance disclosures. Given MLEC trades well below its 200-day MA of 45.85 and 52-week high of 157.05, traders may have focused on the remaining compliance overhang rather than the procedural relief.
Key Terms
nasdaq hearings panel regulatory
reverse stock split financial
form 20-f regulatory
nasdaq capital market regulatory
AI-generated analysis. Not financial advice.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 30, 2026 / Moolec Science S.A. ("Moolec" or the "Company"), a science-based food ingredient company focused on scalable protein solutions for the global market, today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions.
The Panel acknowledged that the Company satisfied the minimum bid price compliance period under Nasdaq Listing Rule 5550(b)(2) on January 16, 2026, following the effectiveness of its reverse stock split on January 5, 2026. The Panel will retain jurisdiction over the bid price matter through May 13, 2026, in accordance with its discretionary authority.
The Panel also noted that the Company filed its Annual Report on Form 20-F for the fiscal year ended June 30, 2025 on December 29, 2025, shortly following the hearing held on December 18, 2025.
With respect to the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), the Panel recognized that the Company has presented a plan that offers a reasonable expectation of regaining compliance within the applicable period.
The continued listing determination is subject to the Company satisfying certain conditions, including (i) the provision of updates to the Panel regarding the status of derecognition proceedings by the end of February 2026, (ii) the delivery of updated pro forma financial information by the end of March 2026, (iii) the timely public disclosure of actions taken to demonstrate compliance with Nasdaq's equity and continued listing requirements by May 13, 2026 and (iv) the Company's demonstration, on or before May 13, 2026, of compliance with all continued listing requirements for the Nasdaq Capital Market.
Moolec intends to fully satisfy the conditions outlined in the Panel's decision and remains focused on maintaining sustained compliance with Nasdaq's continued listing standards, strengthening its financial framework and advancing its strategic priorities.
About Moolec Science SA
Moolec Science is an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food system. By integrating Molecular Farming and precision fermentation, Moolec combines the cost efficiency of crops with the functionality and nutrition of animal proteins, creating sustainable and commercially viable ingredients. The Company's diversified pipeline includes alternative proteins, bioactive compounds, nutritional oils, and biological inputs for regenerative agriculture. Moolec has a robust intellectual property portfolio with more than 118 granted and pending patents across multiple technology platforms. With operations spanning the United States, Europe and South America, Moolec is advancing a seed-to-ingredient approach designed to transform the future of food production. Moolec is publicly listed on Nasdaq under the ticker "MLEC." For more information, please visit www.moolecscience.com and ir.moolecscience.com.
Forward-looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to regain compliance under the Nasdaq rules, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Contact: ir@moolecscience.com (+5493412034927)
SOURCE: Moolec Science
View the original press release on ACCESS Newswire
FAQ
What did Nasdaq decide for Moolec Science (MLEC) on January 30, 2026?
Has MLEC satisfied the Nasdaq minimum bid price requirement and when?
What filing did Moolec file that the Panel noted and when was it filed?
What conditions must MLEC meet to maintain Nasdaq listing by May 13, 2026?
How does the Panel view MLEC's plan to regain stockholders' equity compliance?
